InMode Ltd.

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ABT has a market cap of 220.4B. Regarding current trading prices, INMD is priced at $14.72, while ABT trades at $126.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ABT's P/E ratio is 15.89. In terms of profitability, INMD's ROE is +0.25%, compared to ABT's ROE of +0.32%. Regarding short-term risk, INMD is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check ABT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, INMD is priced at $14.72, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, INMD's ROE is +0.25%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, INMD is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BSX-PA's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BSX has a market cap of 157.1B. Regarding current trading prices, INMD is priced at $14.72, while BSX trades at $106.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BSX's P/E ratio is 63.20. In terms of profitability, INMD's ROE is +0.25%, compared to BSX's ROE of +0.12%. Regarding short-term risk, INMD is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check BSX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SYK has a market cap of 154.2B. Regarding current trading prices, INMD is priced at $14.72, while SYK trades at $403.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SYK's P/E ratio is 54.39. In terms of profitability, INMD's ROE is +0.25%, compared to SYK's ROE of +0.11%. Regarding short-term risk, INMD is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SYK's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, MDT has a market cap of 119.1B. Regarding current trading prices, INMD is priced at $14.72, while MDT trades at $92.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas MDT's P/E ratio is 25.75. In terms of profitability, INMD's ROE is +0.25%, compared to MDT's ROE of +0.10%. Regarding short-term risk, INMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check MDT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, EW has a market cap of 46.9B. Regarding current trading prices, INMD is priced at $14.72, while EW trades at $80.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas EW's P/E ratio is 33.47. In terms of profitability, INMD's ROE is +0.25%, compared to EW's ROE of +0.45%. Regarding short-term risk, INMD is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check EW's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, DXCM has a market cap of 34.9B. Regarding current trading prices, INMD is priced at $14.72, while DXCM trades at $88.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas DXCM's P/E ratio is 66.91. In terms of profitability, INMD's ROE is +0.25%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, INMD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check DXCM's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, INMD is priced at $14.72, while PHG trades at $26.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PHG's P/E ratio is 87.17. In terms of profitability, INMD's ROE is +0.25%, compared to PHG's ROE of +0.03%. Regarding short-term risk, INMD is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PHG's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, STE has a market cap of 22.7B. Regarding current trading prices, INMD is priced at $14.72, while STE trades at $230.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas STE's P/E ratio is 37.44. In terms of profitability, INMD's ROE is +0.25%, compared to STE's ROE of +0.09%. Regarding short-term risk, INMD is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check STE's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PODD has a market cap of 20.4B. Regarding current trading prices, INMD is priced at $14.72, while PODD trades at $290.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PODD's P/E ratio is 52.22. In terms of profitability, INMD's ROE is +0.25%, compared to PODD's ROE of +0.35%. Regarding short-term risk, INMD is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check PODD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, INMD is priced at $14.72, while ZBH trades at $97.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ZBH's P/E ratio is 21.69. In terms of profitability, INMD's ROE is +0.25%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, INMD is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check ZBH's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, INMD is priced at $14.72, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ABMD's P/E ratio is 65.36. In terms of profitability, INMD's ROE is +0.25%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, INMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check ABMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ALGN has a market cap of 14.9B. Regarding current trading prices, INMD is priced at $14.72, while ALGN trades at $205.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ALGN's P/E ratio is 37.44. In terms of profitability, INMD's ROE is +0.25%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, INMD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ALGN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SNN has a market cap of 13.9B. Regarding current trading prices, INMD is priced at $14.72, while SNN trades at $31.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SNN's P/E ratio is 33.69. In terms of profitability, INMD's ROE is +0.25%, compared to SNN's ROE of +0.08%. Regarding short-term risk, INMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check SNN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, INMD is priced at $14.72, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SWAV's P/E ratio is 78.76. In terms of profitability, INMD's ROE is +0.25%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, INMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check SWAV's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PEN has a market cap of 9B. Regarding current trading prices, INMD is priced at $14.72, while PEN trades at $233.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PEN's P/E ratio is 218.00. In terms of profitability, INMD's ROE is +0.25%, compared to PEN's ROE of +0.04%. Regarding short-term risk, INMD is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PEN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, GMED has a market cap of 7.4B. Regarding current trading prices, INMD is priced at $14.72, while GMED trades at $54.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas GMED's P/E ratio is 40.67. In terms of profitability, INMD's ROE is +0.25%, compared to GMED's ROE of +0.05%. Regarding short-term risk, INMD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check GMED's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BIO has a market cap of 7.2B. Regarding current trading prices, INMD is priced at $14.72, while BIO trades at $264.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BIO's P/E ratio is -3.45. In terms of profitability, INMD's ROE is +0.25%, compared to BIO's ROE of -0.32%. Regarding short-term risk, INMD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BIO's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BIO-B has a market cap of 6.9B. Regarding current trading prices, INMD is priced at $14.72, while BIO-B trades at $247.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, INMD's ROE is +0.25%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, INMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check BIO-B's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, INMD is priced at $14.72, while BRKR trades at $41.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BRKR's P/E ratio is 80.65. In terms of profitability, INMD's ROE is +0.25%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, INMD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BRKR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, INMD is priced at $14.72, while GKOS trades at $94.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas GKOS's P/E ratio is -41.55. In terms of profitability, INMD's ROE is +0.25%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, INMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check GKOS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, INMD is priced at $14.72, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas NARI's P/E ratio is -59.24. In terms of profitability, INMD's ROE is +0.25%, compared to NARI's ROE of -0.18%. Regarding short-term risk, INMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check NARI's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, IRTC has a market cap of 4.3B. Regarding current trading prices, INMD is priced at $14.72, while IRTC trades at $134.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas IRTC's P/E ratio is -42.73. In terms of profitability, INMD's ROE is +0.25%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, INMD is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check IRTC's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, INSP has a market cap of 3.8B. Regarding current trading prices, INMD is priced at $14.72, while INSP trades at $128.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas INSP's P/E ratio is 59.17. In terms of profitability, INMD's ROE is +0.25%, compared to INSP's ROE of +0.10%. Regarding short-term risk, INMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check INSP's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, INMD is priced at $14.72, while ITGR trades at $108.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ITGR's P/E ratio is 46.55. In terms of profitability, INMD's ROE is +0.25%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, INMD is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ITGR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, TMDX has a market cap of 3.7B. Regarding current trading prices, INMD is priced at $14.72, while TMDX trades at $108.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas TMDX's P/E ratio is 76.14. In terms of profitability, INMD's ROE is +0.25%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, INMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check TMDX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, INMD is priced at $14.72, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AXNX's P/E ratio is -709.80. In terms of profitability, INMD's ROE is +0.25%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, INMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check AXNX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PRCT has a market cap of 3.1B. Regarding current trading prices, INMD is priced at $14.72, while PRCT trades at $55.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PRCT's P/E ratio is -32.97. In terms of profitability, INMD's ROE is +0.25%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, INMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PRCT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, INMD is priced at $14.72, while LIVN trades at $43.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas LIVN's P/E ratio is -10.73. In terms of profitability, INMD's ROE is +0.25%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, INMD is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check LIVN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, INMD is priced at $14.72, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas NUVA's P/E ratio is 75.00. In terms of profitability, INMD's ROE is +0.25%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, INMD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check NUVA's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, UFPT has a market cap of 1.9B. Regarding current trading prices, INMD is priced at $14.72, while UFPT trades at $241.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas UFPT's P/E ratio is 29.68. In terms of profitability, INMD's ROE is +0.25%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, INMD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check UFPT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, INMD is priced at $14.72, while ATEC trades at $10.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ATEC's P/E ratio is -9.50. In terms of profitability, INMD's ROE is +0.25%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, INMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ATEC's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CNMD has a market cap of 1.6B. Regarding current trading prices, INMD is priced at $14.72, while CNMD trades at $50.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CNMD's P/E ratio is 13.37. In terms of profitability, INMD's ROE is +0.25%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, INMD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CNMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, INMD is priced at $14.72, while SSII trades at $7.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SSII's P/E ratio is -89.75. In terms of profitability, INMD's ROE is +0.25%, compared to SSII's ROE of -1.05%. Regarding short-term risk, INMD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SSII's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, INMD is priced at $14.72, while AORT trades at $31.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AORT's P/E ratio is -61.59. In terms of profitability, INMD's ROE is +0.25%, compared to AORT's ROE of -0.07%. Regarding short-term risk, INMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check AORT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, INMD is priced at $14.72, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas HSKA's P/E ratio is -62.49. In terms of profitability, INMD's ROE is +0.25%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, INMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check HSKA's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, INMD is priced at $14.72, while AHCO trades at $9.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AHCO's P/E ratio is 16.28. In terms of profitability, INMD's ROE is +0.25%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, INMD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check AHCO's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, INMD is priced at $14.72, while ESTA trades at $42.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ESTA's P/E ratio is -13.59. In terms of profitability, INMD's ROE is +0.25%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, INMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ESTA's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, INMD is priced at $14.72, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SILK's P/E ratio is -18.96. In terms of profitability, INMD's ROE is +0.25%, compared to SILK's ROE of -0.29%. Regarding short-term risk, INMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check SILK's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, INMD is priced at $14.72, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas FNA's P/E ratio is -19.83. In terms of profitability, INMD's ROE is +0.25%, compared to FNA's ROE of -0.36%. Regarding short-term risk, INMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check FNA's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, INMD is priced at $14.72, while TNDM trades at $15.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas TNDM's P/E ratio is -5.70. In terms of profitability, INMD's ROE is +0.25%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, INMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check TNDM's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, IART has a market cap of 1B. Regarding current trading prices, INMD is priced at $14.72, while IART trades at $13.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas IART's P/E ratio is -34.51. In terms of profitability, INMD's ROE is +0.25%, compared to IART's ROE of -0.03%. Regarding short-term risk, INMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check IART's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, INMD is priced at $14.72, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CSII's P/E ratio is -20.83. In terms of profitability, INMD's ROE is +0.25%, compared to CSII's ROE of -0.14%. Regarding short-term risk, INMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check CSII's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SIBN has a market cap of 735.1M. Regarding current trading prices, INMD is priced at $14.72, while SIBN trades at $17.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SIBN's P/E ratio is -27.38. In terms of profitability, INMD's ROE is +0.25%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, INMD and SIBN have similar daily volatility (1.61).Check SIBN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, INMD is priced at $14.72, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CRY's P/E ratio is 425.71. In terms of profitability, INMD's ROE is +0.25%, compared to CRY's ROE of -0.07%. Regarding short-term risk, INMD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CRY's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, IRMD has a market cap of 716.1M. Regarding current trading prices, INMD is priced at $14.72, while IRMD trades at $56.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas IRMD's P/E ratio is 36.34. In terms of profitability, INMD's ROE is +0.25%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, INMD is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check IRMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SMLR has a market cap of 695.1M. Regarding current trading prices, INMD is priced at $14.72, while SMLR trades at $38.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SMLR's P/E ratio is -15.93. In terms of profitability, INMD's ROE is +0.25%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, INMD is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SMLR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AXGN has a market cap of 608.7M. Regarding current trading prices, INMD is priced at $14.72, while AXGN trades at $13.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AXGN's P/E ratio is -83.53. In terms of profitability, INMD's ROE is +0.25%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, INMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check AXGN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, INMD is priced at $14.72, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas APEN's P/E ratio is -9.43. In terms of profitability, INMD's ROE is +0.25%, compared to APEN's ROE of -0.85%. Regarding short-term risk, INMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check APEN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, KIDS has a market cap of 564.7M. Regarding current trading prices, INMD is priced at $14.72, while KIDS trades at $22.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas KIDS's P/E ratio is -12.95. In terms of profitability, INMD's ROE is +0.25%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, INMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check KIDS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AVNS has a market cap of 555.4M. Regarding current trading prices, INMD is priced at $14.72, while AVNS trades at $12.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AVNS's P/E ratio is -1.45. In terms of profitability, INMD's ROE is +0.25%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, INMD is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check AVNS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CBLL has a market cap of 546.8M. Regarding current trading prices, INMD is priced at $14.72, while CBLL trades at $15.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CBLL's P/E ratio is -12.10. In terms of profitability, INMD's ROE is +0.25%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, INMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CBLL's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ZIMV has a market cap of 527.9M. Regarding current trading prices, INMD is priced at $14.72, while ZIMV trades at $18.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ZIMV's P/E ratio is -20.80. In terms of profitability, INMD's ROE is +0.25%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, INMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check ZIMV's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SRDX has a market cap of 514.8M. Regarding current trading prices, INMD is priced at $14.72, while SRDX trades at $36.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SRDX's P/E ratio is -25.71. In terms of profitability, INMD's ROE is +0.25%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, INMD is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SRDX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BFLY has a market cap of 487.2M. Regarding current trading prices, INMD is priced at $14.72, while BFLY trades at $1.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BFLY's P/E ratio is -6.57. In terms of profitability, INMD's ROE is +0.25%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, INMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BFLY's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BFLY-WT has a market cap of 482.5M. Regarding current trading prices, INMD is priced at $14.72, while BFLY-WT trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, INMD's ROE is +0.25%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, INMD is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BFLY-WT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CTKB has a market cap of 467.4M. Regarding current trading prices, INMD is priced at $14.72, while CTKB trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CTKB's P/E ratio is -41.00. In terms of profitability, INMD's ROE is +0.25%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, INMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CTKB's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PACB has a market cap of 462.1M. Regarding current trading prices, INMD is priced at $14.72, while PACB trades at $1.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PACB's P/E ratio is -0.56. In terms of profitability, INMD's ROE is +0.25%, compared to PACB's ROE of -1.70%. Regarding short-term risk, INMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PACB's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, OFIX has a market cap of 441.6M. Regarding current trading prices, INMD is priced at $14.72, while OFIX trades at $11.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas OFIX's P/E ratio is -3.05. In terms of profitability, INMD's ROE is +0.25%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, INMD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check OFIX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BVS has a market cap of 436M. Regarding current trading prices, INMD is priced at $14.72, while BVS trades at $6.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BVS's P/E ratio is -13.69. In terms of profitability, INMD's ROE is +0.25%, compared to BVS's ROE of -0.21%. Regarding short-term risk, INMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BVS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SENS has a market cap of 418.1M. Regarding current trading prices, INMD is priced at $14.72, while SENS trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SENS's P/E ratio is -5.04. In terms of profitability, INMD's ROE is +0.25%, compared to SENS's ROE of -7.46%. Regarding short-term risk, INMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SENS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PTHL has a market cap of 415.4M. Regarding current trading prices, INMD is priced at $14.72, while PTHL trades at $29.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PTHL's P/E ratio is -583.00. In terms of profitability, INMD's ROE is +0.25%, compared to PTHL's ROE of -0.30%. Regarding short-term risk, INMD is less volatile compared to PTHL. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PTHL's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, TMCI has a market cap of 358.6M. Regarding current trading prices, INMD is priced at $14.72, while TMCI trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas TMCI's P/E ratio is -6.71. In terms of profitability, INMD's ROE is +0.25%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, INMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check TMCI's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, NNOX has a market cap of 331.6M. Regarding current trading prices, INMD is priced at $14.72, while NNOX trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas NNOX's P/E ratio is -5.71. In terms of profitability, INMD's ROE is +0.25%, compared to NNOX's ROE of -0.31%. Regarding short-term risk, INMD is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check NNOX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, OM has a market cap of 328.6M. Regarding current trading prices, INMD is priced at $14.72, while OM trades at $18.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas OM's P/E ratio is -0.64. In terms of profitability, INMD's ROE is +0.25%, compared to OM's ROE of -1.45%. Regarding short-term risk, INMD is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check OM's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, VREX has a market cap of 325.8M. Regarding current trading prices, INMD is priced at $14.72, while VREX trades at $7.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas VREX's P/E ratio is -7.62. In terms of profitability, INMD's ROE is +0.25%, compared to VREX's ROE of -0.08%. Regarding short-term risk, INMD is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check VREX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SNWV has a market cap of 324.4M. Regarding current trading prices, INMD is priced at $14.72, while SNWV trades at $37.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SNWV's P/E ratio is -6.08. In terms of profitability, INMD's ROE is +0.25%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, INMD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SNWV's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, RXST has a market cap of 323.9M. Regarding current trading prices, INMD is priced at $14.72, while RXST trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas RXST's P/E ratio is -12.08. In terms of profitability, INMD's ROE is +0.25%, compared to RXST's ROE of -0.10%. Regarding short-term risk, INMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check RXST's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CLPT has a market cap of 317.4M. Regarding current trading prices, INMD is priced at $14.72, while CLPT trades at $11.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CLPT's P/E ratio is -14.78. In terms of profitability, INMD's ROE is +0.25%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, INMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CLPT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CATX has a market cap of 301M. Regarding current trading prices, INMD is priced at $14.72, while CATX trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CATX's P/E ratio is -3.30. In terms of profitability, INMD's ROE is +0.25%, compared to CATX's ROE of -0.27%. Regarding short-term risk, INMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CATX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, NPCE has a market cap of 294.5M. Regarding current trading prices, INMD is priced at $14.72, while NPCE trades at $8.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas NPCE's P/E ratio is -10.95. In terms of profitability, INMD's ROE is +0.25%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, INMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check NPCE's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, QTRX has a market cap of 272.9M. Regarding current trading prices, INMD is priced at $14.72, while QTRX trades at $5.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas QTRX's P/E ratio is -4.72. In terms of profitability, INMD's ROE is +0.25%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, INMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check QTRX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, MASS has a market cap of 266.1M. Regarding current trading prices, INMD is priced at $14.72, while MASS trades at $7.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas MASS's P/E ratio is -3.34. In terms of profitability, INMD's ROE is +0.25%, compared to MASS's ROE of -0.13%. Regarding short-term risk, INMD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check MASS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CERS has a market cap of 265.7M. Regarding current trading prices, INMD is priced at $14.72, while CERS trades at $1.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CERS's P/E ratio is -13.90. In terms of profitability, INMD's ROE is +0.25%, compared to CERS's ROE of -0.35%. Regarding short-term risk, INMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CERS's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, TCMD has a market cap of 245.3M. Regarding current trading prices, INMD is priced at $14.72, while TCMD trades at $10.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas TCMD's P/E ratio is 15.98. In terms of profitability, INMD's ROE is +0.25%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, INMD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check TCMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, VMD has a market cap of 241.9M. Regarding current trading prices, INMD is priced at $14.72, while VMD trades at $6.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas VMD's P/E ratio is 20.40. In terms of profitability, INMD's ROE is +0.25%, compared to VMD's ROE of +0.10%. Regarding short-term risk, INMD is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check VMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, MXCT has a market cap of 239.2M. Regarding current trading prices, INMD is priced at $14.72, while MXCT trades at $2.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas MXCT's P/E ratio is -5.62. In terms of profitability, INMD's ROE is +0.25%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, INMD is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check MXCT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, INMD is priced at $14.72, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas NVRO's P/E ratio is -1.91. In terms of profitability, INMD's ROE is +0.25%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, INMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check NVRO's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BWAY has a market cap of 221.7M. Regarding current trading prices, INMD is priced at $14.72, while BWAY trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BWAY's P/E ratio is 53.32. In terms of profitability, INMD's ROE is +0.25%, compared to BWAY's ROE of +0.07%. Regarding short-term risk, INMD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BWAY's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, CVRX has a market cap of 217.4M. Regarding current trading prices, INMD is priced at $14.72, while CVRX trades at $8.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas CVRX's P/E ratio is -3.90. In terms of profitability, INMD's ROE is +0.25%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, INMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check CVRX's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, INMD is priced at $14.72, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas EYES's P/E ratio is N/A. In terms of profitability, INMD's ROE is +0.25%, compared to EYES's ROE of -0.26%. Regarding short-term risk, INMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check EYES's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, MGRM has a market cap of 205.4M. Regarding current trading prices, INMD is priced at $14.72, while MGRM trades at $5.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas MGRM's P/E ratio is -11.36. In terms of profitability, INMD's ROE is +0.25%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, INMD is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check MGRM's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, INGN has a market cap of 182.8M. Regarding current trading prices, INMD is priced at $14.72, while INGN trades at $6.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas INGN's P/E ratio is -5.91. In terms of profitability, INMD's ROE is +0.25%, compared to INGN's ROE of -0.15%. Regarding short-term risk, INMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check INGN's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, SGHT has a market cap of 180.4M. Regarding current trading prices, INMD is priced at $14.72, while SGHT trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas SGHT's P/E ratio is -3.56. In terms of profitability, INMD's ROE is +0.25%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, INMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check SGHT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, RPID has a market cap of 178.8M. Regarding current trading prices, INMD is priced at $14.72, while RPID trades at $4.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas RPID's P/E ratio is -3.96. In terms of profitability, INMD's ROE is +0.25%, compared to RPID's ROE of -0.56%. Regarding short-term risk, INMD is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check RPID's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, TLSI has a market cap of 173.2M. Regarding current trading prices, INMD is priced at $14.72, while TLSI trades at $4.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas TLSI's P/E ratio is -4.15. In terms of profitability, INMD's ROE is +0.25%, compared to TLSI's ROE of +1.04%. Regarding short-term risk, INMD is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check TLSI's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, PROF has a market cap of 170.7M. Regarding current trading prices, INMD is priced at $14.72, while PROF trades at $5.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas PROF's P/E ratio is -4.69. In terms of profitability, INMD's ROE is +0.25%, compared to PROF's ROE of -0.70%. Regarding short-term risk, INMD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check PROF's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ANIK has a market cap of 164.9M. Regarding current trading prices, INMD is priced at $14.72, while ANIK trades at $11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ANIK's P/E ratio is -15.33. In terms of profitability, INMD's ROE is +0.25%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, INMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ANIK's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ELMD has a market cap of 158.1M. Regarding current trading prices, INMD is priced at $14.72, while ELMD trades at $18.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ELMD's P/E ratio is 23.86. In terms of profitability, INMD's ROE is +0.25%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, INMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check ELMD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, LNSR has a market cap of 155.4M. Regarding current trading prices, INMD is priced at $14.72, while LNSR trades at $13.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas LNSR's P/E ratio is -2.69. In terms of profitability, INMD's ROE is +0.25%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, INMD is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check LNSR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, RCEL has a market cap of 152.5M. Regarding current trading prices, INMD is priced at $14.72, while RCEL trades at $5.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas RCEL's P/E ratio is -2.63. In terms of profitability, INMD's ROE is +0.25%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, INMD is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check RCEL's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, BSGM has a market cap of 147.5M. Regarding current trading prices, INMD is priced at $14.72, while BSGM trades at $4.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas BSGM's P/E ratio is -9.04. In terms of profitability, INMD's ROE is +0.25%, compared to BSGM's ROE of -35.30%. Regarding short-term risk, INMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check BSGM's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, OWLT has a market cap of 135M. Regarding current trading prices, INMD is priced at $14.72, while OWLT trades at $8.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas OWLT's P/E ratio is -5.07. In terms of profitability, INMD's ROE is +0.25%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, INMD is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check OWLT's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, LUNG has a market cap of 134.5M. Regarding current trading prices, INMD is priced at $14.72, while LUNG trades at $3.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas LUNG's P/E ratio is -2.32. In terms of profitability, INMD's ROE is +0.25%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, INMD is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check LUNG's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, AVR has a market cap of 121.2M. Regarding current trading prices, INMD is priced at $14.72, while AVR trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas AVR's P/E ratio is -0.94. In terms of profitability, INMD's ROE is +0.25%, compared to AVR's ROE of -2.92%. Regarding short-term risk, INMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check AVR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, LUCD has a market cap of 119.6M. Regarding current trading prices, INMD is priced at $14.72, while LUCD trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas LUCD's P/E ratio is -0.94. In terms of profitability, INMD's ROE is +0.25%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, INMD is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check LUCD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, INMD is priced at $14.72, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas ICAD's P/E ratio is -20.37. In terms of profitability, INMD's ROE is +0.25%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, INMD is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check ICAD's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, FONR has a market cap of 99.5M. Regarding current trading prices, INMD is priced at $14.72, while FONR trades at $16.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas FONR's P/E ratio is 12.83. In terms of profitability, INMD's ROE is +0.25%, compared to FONR's ROE of +0.09%. Regarding short-term risk, INMD is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for INMD.Check FONR's competition here

INMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, INMD stands at 1B. In comparison, RBOT-WT has a market cap of 98.8M. Regarding current trading prices, INMD is priced at $14.72, while RBOT-WT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

INMD currently has a P/E ratio of 6.60, whereas RBOT-WT's P/E ratio is N/A. In terms of profitability, INMD's ROE is +0.25%, compared to RBOT-WT's ROE of -1.17%. Regarding short-term risk, INMD is less volatile compared to RBOT-WT. This indicates potentially lower risk in terms of short-term price fluctuations for INMD.Check RBOT-WT's competition here